The clinical-stage company reported that its once-daily oral candidate outperformed existing GLP-1 market alternatives in cross-trial comparisons, specifically regarding gastrointestinal side effects. Investors responded to the announcement by pushing shares up 5.2% to $8.54 during premarket trading.

Looking ahead, management intends to coordinate with the Food and Drug Administration to finalize a formal clinical-development roadmap. The company plans to launch a Phase 2 monotherapy study by the first half of 2027 while simultaneously exploring the viability of combining CRB-913 with existing GLP-1 therapies.